Temsirolimus and Rituximab in Patients with Relapsed or Refractory Mantle Cell Lymphoma: a multi-center Phase 2 Study
- Citation:
- Lancet Oncol vol 12 (4) 361-368
- Year:
- 2011
- Type:
- Manuscript
- Funding:
- NCTN
- Endpoint:
- Primary
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- pmc-release
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Book Volume:
- Parents:
- None
- Children:
- None
- Pharmas:
- Grants:
- R01 CA092104, R01 CA092104-07, CA92104, CA25224, U10 CA025224, U10 CA025224-26
- Corr. Author:
- Authors:
- Stephen M. Ansell Hui Tang Paul J. Kurtin Patricia A. Koenig David J. Inwards Keith Shah Steven C. Ziesmer Andrew L. Feldman Radha Rao Mamta Gupta Charles Erlichman Thomas E. Witzig
- Networks:
- Study
- NCCTG-N038H
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 2
- Keywords:
- Mantle Cell Lymphoma, mTOR Inhibitor, Rituximab, Phase 2 Trial